NCT05927610
Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma
Evaluating the Role of Cerebrospinal Fluid (CSF) Cell-free DNA (cfDNA) as a Prognostic Biomarker in Glioblastoma
Memorial Sloan Kettering Cancer Center·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Glioblastoma
- Drug/Device/Intervention
- Lumber Puncture
- Study type
- Observational
- Intervention type
- diagnostic test
Sponsor & location
- Primary sponsor
- Memorial Sloan Kettering Cancer Center
- Location
- New York, United States of America
Timeline & enrollment
- Phase
- N/A
- Start date
- Jun 19, 2023
- End date
- Jun 19, 2028
- Enrollment
- 180 participants
Primary outcome
Overall Survival
Summary
The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA
 (cfDNA) as a prognostic biomarker in glioblastoma (GBM).
ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05927610
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05927610 through Pure Global AI's free database. This phase not specified trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Glioblastoma. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.